KIO-101 / Kiora Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
KIO-101 / Kiora Pharma
NCT05629364: A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease

Terminated
2
4
RoW
KIO-101, DHODH inhibitor
Kiora Pharmaceuticals, Inc.
Dry Eye Disease
01/24
01/24

Download Options